BeiGene and Boehringer Ingelheim have entered into a commercial supply agreement for tislelizumab, BeiGene’s investigational anti-PD-1 antibody.    Under the terms of the supply agreement, Boehringer Ingelheim will manufacture tislelizumab in China under an exclusive multi-year arrangement, with contract extension possible. In addition, BeiGene also obtained certain preferred rights for future capacity expansion by Boehringer Ingelheim in China.   “As we advance tislelizumab towa...